NeuroSense Therapeutics L... (NRSNW)
NeuroSense Therapeutics Statistics
Share Statistics
NeuroSense Therapeutics has 23.99M shares outstanding. The number of shares has increased by null% in one year.
| 23.99M |
| n/a |
| n/a |
| 0.59% |
| n/a |
| 779 |
| 9.6% |
Short Selling Information
The latest short interest is 4.4K, so 0% of the outstanding shares have been sold short.
| 4.4K |
| n/a |
| n/a |
| 2.77 |
Valuation Ratios
The PE ratio is -2.19 and the forward PE ratio is null. NeuroSense Therapeutics's PEG ratio is 0.06.
| -2.19 |
| n/a |
| 0 |
| 9.8 |
| 8.64 |
| -2.2 |
| 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NeuroSense Therapeutics.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.03.
| 2.21 |
| 2.21 |
| 0.03 |
| -0.01 |
| -0.01 |
| -31.84 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| n/a |
| $-600,588.24 |
| 17 |
| 0 |
| n/a |
Taxes
| n/a |
| 0% |
Stock Price Statistics
The stock price has increased by 137.84% in the last 52 weeks. The beta is 1.6, so NeuroSense Therapeutics's price volatility has been higher than the market average.
| 1.6 |
| 137.84% |
| 0.26 |
| 0.25 |
| 61.73 |
| 8,113 |
Balance Sheet
The company has 3.38M in cash and 73K in debt, giving a net cash position of 3.31M.
| 3.38M |
| 73K |
| 3.31M |
| -36.66M |
| n/a |
| n/a |
Cash Flow
In the last 12 months, operating cash flow was -10.13M and capital expenditures -3K, giving a free cash flow of -10.14M.
| -10.13M |
| -3K |
| -10.14M |
| -0.54 |
Margins
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Dividends & Yields
NRSNW does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Scores
| n/a |
| n/a |